This paper analyses the inter-firm R&D network formed in the pharmaceutical biotechnology industry during the 1990s … pharmaceutical biotechnology industry has experienced a significant evolutional change in size and structure during 1991-1998. By … not high implying that the distribution of overall positional advantages in the pharmaceutical biotechnology industry is …

corporations in 377 strategic alliances with 143 VC-backed biotechnology startups, we leverage detailed hand-collected data on CHQ …

biotechnology and pharmaceutical firms. Fifteen control rights are identified to make up the structure of deals with five rights …

-food companies' competitiveness, helping them to integrate biotechnology and offer innovative products. The method used to support … (wine culture, fruticulture, and olive culture subsectors) inquired do not develop biotechnology research. They were all … implementation of biotechnology techniques considered more relevant by respondents were access to capital and specialized human …

-intensive industries such as biotechnology. However, little research has been focused on the social mechanisms that allow innovators to …

cluster policies in Japan, Germany, and France as well as six prominent biotechnology clusters in these countries. Information …

complementary biotechnology innovations. Corporate structure and business models of Large Diversificated Firms (LDFs) and Dedicated … Biotechnology Firms (DBFs). In fact, are at the core of scientific research and practice in the management field. We focus our … and Resource Based Views will be underlined and we therefore elaborate on fundamental variables for decision making and …

In this paper, we examine the determinants of control rights in technology strategic alliances between biotechnology … firms and pharmaceutical corporations, as well as with other biotechnology firms. We undertake three clinical studies and an …